ML-336 |
| カタログ番号GC11348 |
ML-336 は VEEV (ベネズエラ馬脳炎ウイルス) 非構造タンパク質 2 を標的とし、ウイルス RNA の転写と複製を阻害します。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1613465-33-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
IC50: 32, 20, and 41 nM for TC-83, V3526, and Trinidad donkey strains, respectively.
ML-336 is an inhibitor for VEEV-induced cytopathic effect.
Alphaviruses like Venezuelan Equine Encephalitis Virus (VEEV) are positive-sense, enveloped, single stranded RNA viruses that are widely geographically distributed. VEEVs are found to be arthropod-borne viruses that are known to cause arthritis, encephalitis, rash, as well as death in humans.
In vitro: ML336 was identified as a first-in-class probe that inhibited a VEEV-induced cytopathic effect in three strains of the virus, which were V3526, TC-83, and Trinidad donkey, in the low nanomolar range without having cytotoxicity (> 50 μM, selectivity index > 1500). In addition, ML336 could reduce viral titer (more than 7.2 log) dramatically below a 1 μM drug concentration. Furthermore, ML336 showed a favorable in vitro PK profile that included moderate blood-brain barrier permeability. More importantly, ML336 seemed to be able to target the VEEV [1].
In vivo: Currently, there is no animal in vivo data reported.
Clinical trial: So far, no clinical study has been conducted.
Reference:
[1] Chung D et al. ML336: Development of Quinazolinone-Based Inhibitors Against Venezuelan Equine Encephalitis Virus (VEEV). Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD): National Center for Biotechnology Information (US); 2010-2012 Dec 17.
| Cas No. | 1613465-33-0 | SDF | |
| Chemical Name | 2-[(E)-(1,4-dimethyl-2-piperazinylidene)amino]-5-nitro-N-phenyl-benzamide | ||
| Canonical SMILES | CN1CCN(C)C/C1=N\C2=C(C(NC3=CC=CC=C3)=O)C=C([N+]([O-])=O)C=C2 | ||
| Formula | C19H21N5O3 | M.Wt | 367.4 |
| 溶解度 | ≤0.2mg/ml in ethanol;10mg/ml in DMSO;20mg/ml in dimethyl formamide | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7218 mL | 13.6091 mL | 27.2183 mL |
| 5 mM | 0.5444 mL | 2.7218 mL | 5.4437 mL |
| 10 mM | 0.2722 mL | 1.3609 mL | 2.7218 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: ≥95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 12 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *